Literature DB >> 7867582

Stimulation of endosteal bone formation by systemic injections of recombinant basic fibroblast growth factor in rats.

T Nakamura1, K Hanada, M Tamura, T Shibanushi, H Nigi, M Tagawa, S Fukumoto, T Matsumoto.   

Abstract

In vivo effects of basic fibroblast growth factor (bFGF) on bone formation was examined in rats. Daily systemic injections of 100 micrograms/kg bFGF for 7 days caused a marked stimulation of endosteal bone formation in both cortical and secondary cancellous bone areas. Histological examinations revealed that the sequence of responses to the injections of bFGF consisted of three phases: an early increase in the number of preosteoblastic cells over the osteoblastic cell layer (days 1-3), recruitment of osteoblasts from preosteoblastic cells (days 3-5), and an increase in new bone formation (days 5-7). These histological changes in the endosteum correlated closely with histomorphometrical parameters of bone formation, and the endosteal mineral apposition rate was almost unaffected during the initial 4 days but was markedly enhanced after this period. Immunohistochemical examinations using antitransforming growth factor (TGF)-beta 1 antibody demonstrated that immunostaining of preosteoblastic cells for TGF-beta already increased 1 day after bFGF treatment. Distribution of TGF-beta in osteoblasts and bone matrices began to increase on day 3, and all the osteoblasts and new bone matrices were intensively immuno-stained on day 7. These results demonstrate that systemic injections of bFGF in rats stimulate endosteal bone formation, and that the stimulation of bone formation is preceded by an initial increase in preosteoblastic cells with later recruitment of osteoblasts from these cells. Because the distribution of TGF-beta in the endosteal cells is increased by bFGF, the effect of bFGF may at least in part be mediated by TGF-beta. However, the precise mechanism of action of bFGF on bone formation remains to be clarified.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7867582     DOI: 10.1210/endo.136.3.7867582

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  38 in total

Review 1.  Growth regulatory factors and bone.

Authors:  G R Mundy; D Chen; M Zhao; S Dallas; C Xu; S Harris
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

2.  Proteoglycan 4: a dynamic regulator of skeletogenesis and parathyroid hormone skeletal anabolism.

Authors:  Chad M Novince; Megan N Michalski; Amy J Koh; Benjamin P Sinder; Payam Entezami; Matthew R Eber; Glenda J Pettway; Thomas J Rosol; Thomas J Wronski; Ken M Kozloff; Laurie K McCauley
Journal:  J Bone Miner Res       Date:  2012-01       Impact factor: 6.741

3.  Local application of basic fibroblast growth factor into the bone increases bone mass at the applied site in rabbits.

Authors:  K Nakamura; T Kurokawa; T Kato; H Okazaki; K Mamada; K Hanada; Y Hiyama; I Aoyama; T Nakamura; M Tamura
Journal:  Arch Orthop Trauma Surg       Date:  1996       Impact factor: 3.067

Review 4.  Alterations of fracture healing in the diabetic condition.

Authors:  E M Kagel; T A Einhorn
Journal:  Iowa Orthop J       Date:  1996

5.  Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation.

Authors:  A Montero; Y Okada; M Tomita; M Ito; H Tsurukami; T Nakamura; T Doetschman; J D Coffin; M M Hurley
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

6.  The incorporation of bFGF mediated by heparin into PCL/gelatin composite fiber meshes for guided bone regeneration.

Authors:  Ji-hye Lee; Young Jun Lee; Hyeong-jin Cho; Dong Wan Kim; Heungsoo Shin
Journal:  Drug Deliv Transl Res       Date:  2015-04       Impact factor: 4.617

Review 7.  From palliative therapy to prolongation of survival: (223)RaCl2 in the treatment of bone metastases.

Authors:  Knut Liepe; Ajit Shinto
Journal:  Ther Adv Med Oncol       Date:  2016-04-25       Impact factor: 8.168

8.  Angiogenic response induced by acellular femoral matrix in vivo.

Authors:  Maria Teresa Conconi; Beatrice Nico; Piera Rebuffat; Enrico Crivellato; Pier Paolo Parnigotto; Gastone G Nussdorfer; Domenico Ribatti
Journal:  J Anat       Date:  2005-07       Impact factor: 2.610

9.  Exported 18-kDa isoform of fibroblast growth factor-2 is a critical determinant of bone mass in mice.

Authors:  Liping Xiao; Peng Liu; Xiaofeng Li; Thomas Doetschman; J Douglas Coffin; Hicham Drissi; Marja M Hurley
Journal:  J Biol Chem       Date:  2008-12-04       Impact factor: 5.157

10.  Basic fibroblast growth factor has rapid bone anabolic effects in ovariectomized rats.

Authors:  R A Power; U T Iwaniec; K A Magee; N G Mitova-Caneva; T J Wronski
Journal:  Osteoporos Int       Date:  2004-03-30       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.